Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 3,600 Shares

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,600 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the transaction, the director now directly owns 21,641 shares of the company’s stock, valued at $1,022,753.66. This represents a 14.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Twist Bioscience Stock Down 5.3 %

Twist Bioscience stock opened at $36.89 on Friday. Twist Bioscience Co. has a twelve month low of $18.80 and a twelve month high of $60.90. The company’s 50-day moving average price is $43.90 and its 200-day moving average price is $45.91. The company has a market cap of $2.16 billion, a PE ratio of -9.66 and a beta of 1.78.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC bought a new stake in Twist Bioscience in the second quarter worth $43,000. Blue Trust Inc. increased its position in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the second quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on TWST shares. Robert W. Baird upped their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Barclays decreased their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.